Within the matrix metalloproteinase (MMP) family, gelatinase B or MMP-9 is suggested as a novel therapeutic target for the treatment of IBD, because MMP-9 expression is associated with disease development and is reduced by efficient treatment, as recently reviewed3. This evidence concerns the gene MMP9 and inflammatory bowel disease.